NCBI PubMed Central
open access
Do Chemically Modified Oligonucleotide Therapeutics Require Environmental Risk Assessment?
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective.#157920
- Sydnone-modified nucleosides as versatile tools for bioorthogonal post-synthetic functionalization of antisense oligonucleotides#923047
- Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia#1074002
- An End-to-End Synthetic Oncology Clinical Trial Framework Integrating Radiographic Response, Circulating Tumor DNA, Safety, and Survival for Decision-Oriented Clinical Data Science#164879
- An End-to-End Synthetic Oncology Clinical Trial Framework Integrating Radiographic Response, Circulating Tumor DNA, Safety, and Survival for Decision-Oriented Clinical Data Science#160452
Record · ID 472562
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive